三年在线观看免费观看,日本成本人片不卡无码免费,成品人和精品人的区别三叶草,欧美国产日韩a在线视频y

Your location:Home > Newsroom > Industry News

ADL launches urine-based diagnostic test to detect precursor to colorectal cancer


 

MDBR Staff Writer

Published 29 June 2016

Atlantic Diagnostic Laboratories (ADL) announced the official launch of PolypDx, a non-invasive urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal cancer. It is estimated that there will be 134,490 new cases reported this year.

With early detection in the adenomatous polyp stage, this form of cancer is preventable. Early detection will save lives and reduce treatment costs.

"ADL, with its extensive LC/MS/MS expertise, is very excited to be offering the PolypDx non-invasive urine test for its official launch into America," said Aaron Domenico, Chief Operating Officer of ADL.

"Colorectal cancer is a leading cause of death in the United States. With early detection in the adenomatous polyp stage, this form of cancer is preventable."

PolypDx gives doctors a new tool in the prevention of colorectal cancer. In a Canadian-based clinical trial of nearly 1,000 patients, MTI's PolypDx demonstrated significantly higher sensitivity than current fecal-based screening tests to detect adenomatous polyps.

Once screened, patients presenting a risk of adenomatous polyps can be directed to a colonoscopy, during which the adenomatous polyps can be completely and safely removed, thus preventing the progression into colorectal cancer.

PolypDx is a simple and effective test requiring only a small urine sample. Early detection and non-invasive ease of use are key distinguishing factors for a screening test in the prevention of colorectal cancer.

PolypDx is the flagship product of Metabolomic Technologies Inc. (MTI), a privately held Canadian company based in Edmonton, Alberta. MTI has signed a multi-million dollar agreement with ADL giving them the exclusive licensing and distribution rights to bring PolypDx into the US market.

"The partnership and collaboration between MTI and Atlantic Diagnostic Laboratories will provide the opportunity for patients to access a simple and accurate test with proven capacity to detect adenomatous colonic polyps and thereby prevent colon cancer," said Dr. Richard Fedorak, President of MTI.

ADL is a full service clinical laboratory with headquarters in the suburbs of Philadelphia providing microbiology, chemistry, toxicology, immunology, virology and molecular testing in 12 states: Pennsylvania, New Jersey, Connecticut, New York, District of Columbia, Delaware, Maryland, Virginia, Florida, Ohio, Kentucky and West Virginia.

About AVE   |   Newsroom   |   Products   |   Service   |   Contact Us
◎China. Changsha. AVE Science & Technology Co.Ltd. All Rights Reserved
<label id="pmmrb"></label>

<ul id="pmmrb"></ul>

    主站蜘蛛池模板: 兴和县| 柳河县| 新宾| 海伦市| 泽普县| 香格里拉县| 和林格尔县| 阳朔县| 城步| 固阳县| 呼玛县| 汉阴县| 当雄县| 东港市| 邹平县| 龙游县| 昌吉市| 淅川县| 平陆县| 新安县| 永靖县| 沧州市| 泰顺县| 邵阳县| 马关县| 罗平县| 察哈| 新兴县| 延寿县| 嘉善县| 黄龙县| 临泽县| 陆河县| 合阳县| 翁牛特旗| 泽库县| 福建省| 大足县| 科尔| 鄂州市| 揭西县|